Product

Daratumumab / Hyaluronidase

Aliases

Daratumumab / Hyaluronidase Injection

2 clinical trials

2 indications

Indication

T-cell Acute Lymphoblastic Leukemia

Indication

Hemolytic Anemia

Clinical trial

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL

Status: Recruiting, Estimated PCD: 2024-10-31

Clinical trial

The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia

Status: Active (not recruiting), Estimated PCD: 2024-12-01